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Background: Plasmodium vivax is a predominant species of malaria in parts of South America and there is
increasing resistance to drugs to treat infections by P. vivax. The existence of latent hypnozoites further complicates
the ability to classify recurrent infections as treatment failures due to relapse, recrudescence of hyponozoites or
re-infections. Antigen loci are putatively under natural selection and may not be an optimal molecular marker to
define parasite haplotypes in paired samples. Putatively neutral microsatellite loci, however, offer an assessment of
neutral haplotypes. The objective here was to assess the utility of neutral microsatellite loci to reconcile cases of
recurrent parasitaemia in Amazonian P. vivax populations in Peru.
Methods: Patient blood samples were collected from three locations in or around Iquitos in the Peruvian Amazon.
Five putatively neutral microsatellite loci were characterized from 445 samples to ascertain the within and amongst
population variation. A total of 30 day 0 and day of recurrent parasitaemia samples were characterized at
microsatellite loci and five polymorphic antigen loci for haplotype classification.
Results: The genetic diversity at microsatellite loci was consistent with neutral levels of variation measured in other
South American P. vivax populations. Results between antigen and microsatellite loci for the 30 day 0 and day of
recurrent parasitaemia samples were the same for 80% of the pairs. The majority of non-concordant results were
the result of differing alleles at microsatellite loci. This analysis estimates that 90% of the paired samples with the
same microsatellite haplotype are unlikely to be due to a new infection.
Conclusions: A population-level approach was used to yield a better estimate of the probability of a new infection
versus relapse or recrudescence of homologous hypnozoites; hypnozoite activation was common for this cohort.
Population studies are critical with the evaluation of genetic markers to assess P. vivax biology and epidemiology.
The additional demonstration of microsatellite loci as neutral markers capable of distinguishing the origin of the
recurrent parasites (new infection or originating from the patient) lends support to their use in assessment of
treatment outcomes.
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Plasmodium vivax contributes to a significant amount of
morbidity in the Peruvian Amazon, accounting for 90%
of all reported malaria cases in 2011 [1]. P. vivax is a
predominant Plasmodium species in most areas of South
America. The presence of the dormant hypnozoite stage
along with reports of resistance to the most commonly* Correspondence: amccollum@cdc.gov
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article, unless otherwise stated.used drugs to treat the blood stage, complicating treatment
options for P. vivax complicate treatment options. Accord-
ingly, the treatment and control of P. vivax remains an im-
portant issue to public health programmes.
P. vivax is characterized by the presence of a hypnozoite
stage, which can persist in the liver for months to years,
causing recurrent disease even though treatment and
clearance of the initial blood stage infection were achieved.
When a patient presents with recurrent P. vivax para-
sitaemia following treatment, there are several possible
causes: 1) recrudescence of blood stage parasites; 2) relapsetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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patient resides in an endemic area). Previous studies
have shown that the risk and timing of relapse depends
on the geographical origin of the initial infection. It is
known that isolates of P. vivax from the tropics relapse
sooner than those from more temperate areas, with 70%
of relapses occurring within five months of initial infection
[2]. The probability of relapse is higher than 20% for
P. vivax patients when anti-hypnozoite therapy is not
prescribed, and, thus, the ability to distinguish between
relapse, recrudescence and re-infection is important in
clinical efficacy studies [3].
Molecular genotype profiles of the parasites in an in-
fection are critical to the assessment of clinical efficacy
studies. These profiles may also be used to estimate the
rate of new infections in populations that are continuously
exposed. Increasingly, molecular genotyping has been
used to differentiate treatment recrudescence from re-
infection by comparing the profiles or haplotypes in a
paired patient samples [4,5]. The probability that a given
haplotype is identical in paired samples taken from two
different time points greatly decreases with the use of a
greater number of genetic loci and, also, with loci that
have a high amount of polymorphism within a parasite
population [6]. Using antigen-encoding genes is problematic
as they are affected by immune selection. These genes
alone or in concert are not able to distinguish recrudes-
cence from re-infection with high levels of confidence [2].
Highly variable neutral microsatellite loci are ideal tools
to assess population-level studies of Plasmodium falcip-
arum and, more recently, P. vivax [7-16]. Complicating
factors include the existence of multiple infections or clones
within a single host and, in the case of P. vivax, the pres-
ence of dormant hypnozoites that persist for some time
after the initial infection. However, studies that employ
population level sampling and estimates of variation at
each of the loci, in addition to paired patient samples
taken at different points in time during an infection, can
yield estimates of recurrence and drug failures [9,15]. An
analysis of P. vivax populations and recurrent parasitemia
was conducted. The haplotypes and the genetic variation
allow for further assessment of paired patient samples as
recrudescence/relapse or new infection.
Methods
Study sites and collection of samples
Samples were collected under a study aimed at assessing
the efficacy of three doses of primaquine for the preven-
tion of P. vivax relapses. The study was conducted from
March 2006 to November 2007 in three sites, Padrecocha,
Santa Clara and San Juan, located in or near the city of
Iquitos, the largest city in the Peruvian Amazon (Figure 1).
Patients included in the study were at least one year of
age, had a fever or history of fever within 72 hours, had amono-infection with P. vivax as assessed by microscopy
and PCR [17], had parasitaemia levels ranging between
250 and 100,000 asexual parasites/ul, were not pregnant,
did not present with symptoms of severe malaria, and had
normal activities of glucose-6-phosphate dehydrogenase
(G6PD). All patients were treated under direct observation
with chloroquine (25 mg/kg) over three days and three
regimens of primaquine, depending on the study arm.
Prior to receiving treatment, a pre-treatment whole blood
sample was obtained on day 0 (D-0). Patients who pre-
sented a second time in the subsequent six months with
recurrent P. vivax parasitaemia were treated with a second
round of primaquine-chloroquine according to the proto-
col of the Peruvian Ministry of Health, and a second
sample of whole blood was collected prior to re-treatment
on the day of recurrence (D-R). All samples were stored
at −80°C until they were used. Informed consent was
granted by the subject or guardian in the case of minors
and assent was obtained from subjects between eight and
17 years of age. The study protocol was approved by
the Ethical Review Committees of the Peruvian National
Institute of Health and the US Naval Medical Research
Center in compliance with all applicable Federal regulations
governing the protection of human subjects.
DNA extraction
Parasitic DNA was extracted from 200 μl of whole blood
following instructions from QIAamp DNA Blood Mini
Kit (Qiagen). Genomic P. vivax DNA was used in order
to amplify the polymorphic antigenic loci and also for
the neutral microsatellite analysis.
Antigen genotyping of Plasmodium vivax
Thirty paired samples (D-0 and D-R from the same subject)
were genotyped for five polymorphic antigenic loci of
P. vivax: apical membrane antigen-1 (Pvama1) [18], cir-
cumsporozoite protein (Pvcsp) [19], merozoite surface pro-
tein 1 (Pvmsp-1) [20], merozoite surface protein 3 (Pvmsp3)
[21], and duffy receptor binding protein (Pvdbp) [22].
Products of single PCR reactions were sequenced using an
Applied Biosystems Prism 3130xl Avant Genetic Analyzer,
and data analysis was performed using Sequencer software
(Gene Codes Corporation).
Microsatellite characterization
Microsatellite characterization was conducted on 445
samples from 355 subjects (355 D-0 samples and 90 D-R
samples) using five microsatellite loci in the P. vivax gen-
ome published previously by Imwong et al.: 14.185, 12.335,
7.67, 6.34, and 3.35 [10]. The full panel of eleven loci in the
original study by Imwong et al., were tested, but these five
loci were chosen because they reliably produced a product
on a multitude of specimens and spurious peaks were rarely
detected. Further, these loci amplified a polymorphic loci in
Figure 1 A map of the three populations used in this study, Padrecocha, Santa Clara, and San Juan.
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in the laboratory. The published PCR protocol was
modified by using the PCR MasterMix (Promega) [10].
Fluorescently labelled PCR products were analysed on an
Applied Biosystems Prism 3130xl Avant Genetic Analyzer
and analysed using GeneMapper v4.0 (Applied Biosystems).
A minimum peak height of 200 fluorescent units was used
to define amplification products. For all analyses that use
the microsatellite data, if multiple peaks were detected for a
single sample, the value of the highest peak was used for
the analysis.
Statistical analysis
The genetic variation for each microsatellite locus was
measured by calculating the expected heterozygosity (He)
and number of alleles per microsatellite locus (A). He was
calculated for each locus as He = [n/(n − 1)][1 − ∑ pi
2],
where n is the number of isolates sampled and pi is the
frequency of the ith allele. The sampling variance for He
was calculated as 2(n − 1)/n3[2(n − 2)[∑ pi
3 − (∑ pi
2)2]] [23].
He and the sampling variance were calculated using D-0
samples only. Arlequin ver 3.01 was used to compute He
[24], and the Excel Microsatellite Toolkit was used to
format data [25].
Wright’s fixation index, FST, was used to test for genetic
differentiation between two populations [26]. FST was
calculated using Arlequin version 3.01 [24]. Linkage
disequilibrium (LD) between microsatellite loci was
assessed by using an exact test of LD [27]. AssociationsTable 1 Heterozygosity (He) and number of alleles (A) per mic
Locus 14.185 12.335 7.67
He A He A He
Padrecocha 0.6833 ± 0.000 4 0.8430 ± 0.000 12 0.714
Santa Clara 0.7279 ± 0.001 6 0.8714 ± 0.000 11 0.707
San Juan 0.7282 ± 0.000 7 0.8665 ± 0.000 14 0.722
All 0.7173 ± 0.000 7 0.8665 ± 0.000 17 0.716were tested between pairs of loci or sites by using 10,000
Monte Carlo steps in Arlequin; a Bonferroni-Holm cor-
rection was used to correct for multiple testing. For both
FST and LD calculations, only microsatellite haplotypes
from D-0 samples were used for the analyses. If a locus
had multiple peaks, the allele represented by the highest
peak was used for the analyses.
For paired D-0 and D-R samples, P(match), the probabil-
ity of a second infection with a particular haplotype occur-
ring purely by chance, was calculated using the population
haplotype frequency. This calculation follows Brockman
et al. and was conducted for the post-treatment sample
pairs that had the same haplotype at each time point [28].
P(match) was calculated only for those sample pairs where
the five-locus data was available; if data were missing from
any of the loci then the paired samples were not considered
for the P(match) analysis. Considering each geographic
population separately, haplotype frequencies were deter-
mined using the five microsatellite loci and D-0 samples
only. These frequencies were used as the ‘P(match)’ value
for each of the haplotypes in question, and the P(match)
value was considered significant if <0.05.
Results
Genetic relationships and differentiation among
populations
In order to characterize the genetic variation overall and
for each individual population, 355 D-0 samples were char-
acterized at five neutral microsatellite loci. A total of 117,rosatellite locus
6.34 3.35
A He A He A
9 ± 0.001 11 0.7711 ± 0.000 7 0.7998 ± 0.000 12
2 ± 0.002 9 0.7973 ± 0.000 7 0.8197 ± 0.001 10
7 ± 0.001 15 0.7775 ± 0.001 9 0.8071 ± 0.000 14
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Figure 2 Linkage disequilibrium between microsatellite loci at
the three sites, Padrecocha (A), Santa Clara (B), and San Juan
(C). Each box represents one comparison between polymorphic
pairs of loci. Shaded cells represent significance at 0.01.
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loci from Padrecocha, Santa Clara, and San Juan, respect-
ively. Approximately 2% of the samples in Padrecocha and
San Juan and 3% in Santa Clara represented mixed in-
fections of multiple P. vivax strains or haplotypes. He, a
measure of genetic variation per locus, was between
0.68 and 0.87 for each of the three populations individually
and as a whole (Table 1). The loci 12.335, 7.67 and 3.35 had
a higher number of alleles in each population and 14.185
and 6.34 had lower numbers of alleles.
There was a significant amount of genetic differentiation
(measured by FST) between Padrecocha and San Juan
P. vivax populations (0.0118, p < 0.01). Additionally, the
Padrecocha and San Juan P. vivax populations showed
pairwise LD at all five loci. The Santa Clara population
exhibited less LD (Figure 2).
Analysis of paired samples
A total of 30 paired samples collected at the D-0 and D-R
visits were analysed for P. vivax strain identity using five
polymorphic antigenic loci (PAL): Pvama, Pvcsp, Pvmsp1,
Pvmsp3, and Pvdbp. Twelve (40%) paired samples had
identical antigenic haplotypes and 18 (60%) had at least one
locus that differed between the paired samples (Table 2).
Ninety paired D-0 and D-R samples were analysed for P.
vivax strain identity by using the five loci microsatellite
haplotypes (Table 3). Fifty percent of all pairs had identical
alleles at all loci and the same proportion had a different
allele at a minimum of one locus (Table 2). These propor-
tions were similar for each of the three populations indi-
vidually. A total of 37/41 paired samples (90.2%) had a
significant P(match) < 0.05. Thus, it was unlikely that
90.2% of the paired samples were the result of a new infec-
tion. It should be noted that P(match) was only calculated
for 41 out of 45 total pairs where the haplotypes were the
same. Four pairs had incomplete data, and thus were
removed from P(match) calculations.
The microsatellite data were compared to the PAL data
for 30 paired samples. Concordance between the paired
samples was examined for both PAL and microsatellite
data (both having the criteria of no differing loci for a D-0
and D-R pair). Twenty-four pairs (24/30, 80%) had con-
cordant results between the two methods and six pairs
(six/30, 20%) were non-concordant. Of the six that were
non-concordant, one pair was determined as the same
haplotype by microsatellite analysis at both time points
and a different haplotype by antigen loci (the difference
was at one of five loci, Pvcsp). Five pairs were found to
have the same haplotype by antigen loci but a different
haplotype by using microsatellite loci.
Discussion
The high levels of genetic diversity seen in these samples
from the Peruvian Amazon are consistent with neutrallevels of microsatellite and tandem repeat variation mea-
sured in P. vivax from multiple sites in Brazil, Colombia,
and Peru [7,13,15,29-32]. This pattern is curious because
it is entirely different from South American P. falciparum
populations, as they show much lower levels of variation
[33]. These differences could be explained by a number of
Table 2 Summary of polymorphic antigen loci (PAL) and microsatellite haplotypes from paired D-0 and D-R samples
Padrecocha Santa Clara San Juan Total
Number pairs with differenta PAL haplotype (%) 13 (65) 2 (100) 3 (37.5) 18 (60)
Number pairs with sameb PAL haplotype (%) 7 (35) 0 (0) 5 (62.5) 12 (40)
Number pairs with differenta microsatellite haplotype (%) 19 (55.9) 5 (50) 21 (45.7) 45 (50)
Number pairs with sameb microsatellite haplotype (%) 15 (44.1) 5 (50) 25 (54.3) 45 (50)
Number pairs where p(match) <0.05 (%) 9 (69)c 5 (100) 23 (100)c 37 (90.2)
aDifferent is defined as having at least one out of five loci different between paired samples.
bSame is defined as having identical alleles at all loci from which a viable PCR product was obtained.
cp (match) was only calculated for samples where there was complete data; two paired samples in both Padrecocha and San Juan populations had
incomplete data.
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selection due to drug pressure or differences in micro-
satellite dynamics between the two Plasmodium species.
A low number of multiple clone infections in individual
patients were observed in this study. This is an area where
there is relatively lower transmission of parasites, and
it is expected that these patients would experience less
inoculations than patients in a hyperemic area of disease,
and, thus a reduced chance for multiple clones existing
within a single patient. Further, the specific composition
of loci examined (i.e. the microsatellite motifs) and the
effects of natural selection (i.e. strong immune selection
on PALs) on these loci, may affect the detection of multiple
infections [34].
There was evidence of population differentiation be-
tween Padrecocha and San Juan; this differentiation was
not observed between Santa Clara and either of the two
sites. This result could be due to a sample size bias, as only
54 samples were available from Santa Clara. Extensive LD
among microsatellite markers has been noted in Colombian
and some (but not all) Brazilian P. vivax populations.
The existence of LD in South American populations is not
surprising, given the low rate of parasite transmission and
high levels of genetic inbreeding documented in many
areas of the continent [13,29,35]. The Santa Clara popula-
tion had less observed LD, but this population was repre-
sented by a smaller number of samples, which could affect
the calculation of LD as it is dependent on the frequency
of allele or loci pairs in a population. An alternative ex-
planation could be that the Santa Clara population has
experienced a larger amount of genetic recombination
or mutation. Additional studies would be needed to better
understand this observation.
There have been several studies that have utilized
population-based estimates of genetic variation to calculate
the probability that a pair of samples from the same patient
would have the same genetic profile or haplotype by
chance. P (identical), the probability that a random pair of
haplotypes is identical, is affected by low frequency haplo-
types in a population [36]. There are many low frequency
haplotypes in each of the three Peruvian populationsevaluated here. Another estimate, p (maximum), the max-
imum probability of two clones carrying the same haplo-
type by chance, requires independence of loci [9]. There
was extensive LD between loci in the populations from
Padrecocha and San Juan; thus, non-independence of
loci was found. The third method, P(match), utilizes the
population haplotype frequencies to assess whether the
paired haplotype frequency occurs above or below a
defined frequency value (for example, 0.05) [28]. Given
the before mentioned limitations of the populations, P
(match) was chosen as a method to assess the maximum
probability of two clones or parasites carrying the same
haplotype by chance in a population. P(match) has the
limitation of requiring a population-level assessment of
parasite diversity prior to assigning probability values.
In areas with low genetic diversity, as is observed in
South America, sample sizes must be relatively large in
order to appropriately define the extent of diversity in the
parasite populations [28].
Eighty percent of the paired samples examined by both
microsatellite and antigen loci methods obtained the same
overall result. Five out of six non-concordant paired sam-
ples (83%) were found to have different haplotypes at the
two sampling times by microsatellite loci, but not by using
antigen loci. This result is not unexpected, as microsatel-
lite loci are putatively neutral with respect to selection,
and, thus, should exhibit a greater amount of variation.
Loci under strong selection, such as antigen loci, exhibit
lower levels of variation in the population. These results
emphasize the utility of using neutral loci to determine
the P. vivax strain characteristics, and this can be illustrated
by considering the application of these tests to assess a
treatment regimen. If, for example, this study assessed
drug failures amongst these 30 paired samples, results
from antigen-encoding loci would lead one to believe that
12 (40%) patients potentially had a relapse of liver-stage
parasites, whereas microsatellite loci would assess this rate
at eight (26.7%) patients. It should be emphasized, though,
that this type of simple interpretation has many caveats.
Of note, the microsatellite methods used here employed a
population-based level of sampling and analysis - such an
Table 3 Microsatellite analysis of paired D-0 and D-R samples
Population Case Treatmenta Dayb 14.185c 12.335 7.67 6.34 3.35 MS finald p(match)e
Padrecocha 1 5 0 269 162 102 150 125 S 0.01
70 269 162 102 150 125
2 5 0 269 160 100 135 127 D
183 269 166 100 160 127
3 5 0 135 D
141 160
4 7 0 265 171 102 150 S
84 265 171 102 150
5 14 0 265 171 135 D
83 265 166 135
6 5 0 269 158 127 146 125 D
154 269 158 127 150 151
7 5 0 282 162 100 146 D
105 265 171 102 150
8 14 0 282 166 100 135 135 D
81 265 171 102 150 151
9 7 0 282 166 160 D
28 282 166 135
10 7 0 282 162 101 150 151 D
43 282 166 101 135 133
11 5 0 282 163 98 150 151 D
120 282 163 98 150 153
12 14 0 282 166 135 133 D
55 282 166 160 127
13 5 0 269 158 126 146 125 D
154 269 158 126 135 127
14 5 0 269 158 125 145 125 S 0.051
210 269 158 125 145 125
15 14 0 282 166 160 125 D
43 282 166 135 133
16 7 0 282 166 102 135 133 D
105 269 162 102 160 125
17 5 0 282 166 122 150 117 D
53 282 166 101 135 125
18 5 0 269 166 101 160 127 D
63 282 162 101 146 125
19 14 0 265 171 102 150 153 S 0.02
91 265 171 102 150 153
20 5 0 265 171 102 150 153 D
84 265 171 102 146 125
21 5 0 269 158 125 145 125 S 0.031
111 269 158 125 145 125
22 5 0 269 158 125 145 125 S 0.031
126 269 158 125 145 125
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Table 3 Microsatellite analysis of paired D-0 and D-R samples (Continued)
23 14 0 269 159 100 135 127 S 0.01
73 269 159 100 135 127
24 5 0 265 170 102 150 153 D
70 265 170 102 150 125
25 7 0 265 170 101 150 153 S 0.01
53 265 170 101 150 153
26 7 0 265 170 102 149 153 S 0.051
76 265 170 102 149 153
27 14 0 265 149 153 D
52 265 134 131
28 5 0 265 170 102 149 153 S 0.051
112 265 170 102 149 153
29 7 0 265 170 102 149 153 S 0.051
80 265 170 102 149 153
30 14 0 265 170 102 149 153 S 0.051
67 265 170 102 149 153
31 7 0 265 170 102 149 153 S 0.051
120 265 170 102 149 153
32 5 0 265 136 125 D
63 265 134
33 5 0 265 170 102 150 153 S 0.01
202 265 170 102 150 153
34 7 0 265 149 S
121 265 149 153
Santa Clara 35 7 0 265 162 98 150 151 D
52 265 164 102 135 127
36 5 0 265 162 100 135 119 D
126 265 162 100 135 127
37 5 0 265 171 102 150 153 D
87 265 171 102 150 151
38 14 0 265 164 101 150 135 D
134 265 164 101 150 125
39 5 0 265 170 102 149 153 S 0.019
30 265 170 102 149 153
40 5 0 265 160 125 D
38 265 160 153
41 14 0 265 158 125 145 125 S 0.019
178 265 158 125 145 125
42 5 0 265 158 126 145 125 S 0.019
117 265 158 126 145 125
43 5 0 265 170 102 149 127 S 0.019
110 265 170 102 149 127
44 14 0 265 164 115 149 125 S 0.019
32 265 164 115 149 125
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Table 3 Microsatellite analysis of paired D-0 and D-R samples (Continued)
San Juan 45 7 0 265 150 D
28 265 135
46 5 0 265 162 102 150 127 D
43 265 171 102 150 151
47 5 0 265 166 122 150 127 S 0.006
71 265 166 122 150 127
48 7 0 265 166 122 150 117 D
40 265 164 104 135 125
49 5 0 265 164 102 135 D
62 265 164 102 135
50 14 0 265 158 102 135 127 D
84 265 171 102 150 127
51 5 0 265 171 102 150 127 S 0.006
70 265 171 102 150 127
52 5 0 265 171 102 150 151 S 0.006
80 265 171 102 150 151
53 14 0 265 164 101 160 125 S 0.012
99 265 164 101 160 125
54 14 0 265 158 125 149 125 D
144 265 158 125 145 125
55 5 0 265 160 102 145 151 D
86 265 160 102 145 151
56 5 0 265 162 102 135 151 S 0.006
51 265 162 102 135 151
57 5 0 265 170 100 150 127 S 0.006
53 265 170 100 150 127
58 5 0 265 174 100 134 119 S 0.006
53 265 174 100 134 119
59 7 0 265 160 160 125 S
120 265 160 160 125
60 5 0 265 162 101 150 149 S 0.006
72 265 162 101 150 149
61 7 0 265 134 D
99 265 134
62 7 0 265 170 100 159 153 S 0.006
129 265 170 100 159 153
63 5 0 265 174 102 134 125 S 0.006
42 265 174 102 134 125
64 5 0 265 149 121 D
122 265 159 121
65 14 0 265 166 101 134 121 S 0.006
98 265 166 101 134 121
66 14 0 265 174 100 149 133 D
56 265 170 102 149 133
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Table 3 Microsatellite analysis of paired D-0 and D-R samples (Continued)
67 14 0 265 166 151 134 127 S 0.006
100 265 166 151 134 127
68 5 0 265 158 122 149 127 D
113 265 158 122 149 127
69 5 0 265 159 121 D
85 265 149 121
70 14 0 265 166 121 134 121 S 0.006
76 265 166 121 134 121
71 5 0 265 101 145 D
210 265 164 105 150
72 5 0 265 162 100 160 153 S 0.006
162 265 162 100 160 153
73 7 0 265 166 99 135 D
71 265 162 121 149
74 5 0 265 164 101 160 125 S 0.012
103 265 164 101 160 125
75 5 0 265 166 101 134 D
197 265 162 101 134
76 5 0 265 170 102 150 125 S 0.006
72 265 170 102 150 125
77 5 0 265 166 100 160 125 S 0.006
56 265 166 100 160 125
78 5 0 265 135 133 D
168 265 135 148
79 14 0 265 158 125 134 127 D
80 265 154 125 134 151
80 7 0 265 170 101 149 125 D
51 265 166 121 149 125
81 5 0 265 134 S
136 265 134 121
82 5 0 265 145 D
59 265 135 151
83 5 0 265 174 102 149 133 D
163 265 170 102 149 148
84 7 0 269 162 103 145 153 S 0.006
168 269 162 103 145 153
85 14 0 269 162 100 149 148 S 0.006
71 269 162 100 149 148
86 14 0 265 167 101 149 153 S 0.006
98 265 167 101 149 153
87 5 0 269 162 121 149 127 S 0.006
136 269 162 121 149 127
88 5 0 269 166 101 135 153 S 0.006
79 269 166 101 135 153
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Table 3 Microsatellite analysis of paired D-0 and D-R samples (Continued)
89 14 0 271 166 101 134 121 D
183 276 162 100 140 148
90 14 0 282 162 100 160 153 S 0.006
73 282 162 100 160 153
aTreatment given to the patient on D-0. ‘5’ represents 30 mg of primaquine for 5 days; ‘7’ represents 30 mg of primaquine for 7 days.
‘14’ represents 15 mg of primaquine for 14 days.
bDay of sample collection, where ‘0’ is Day-0 (D-0) and the second day is the day of recurrence (D-R) respective to D-0.
cAllele for each microsatellite loci are reported as PCR product size.
dThe final determination of concordance (S = same) or disconcordance (D = different) between the two microsatellite haplotypes (D-0 and D-R). Different alleles
between a pair of samples are highlighted in red.
eP(match) values were calculated separately for each population and only for complete 5-locus haplotypes.
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variation. Although use of PAL and microsatellite loci can
be used in conjunction, researchers should use caution in
the interpretation of the data and consider the effect of
selection or neutral mechanisms on each of type of loci.
Interpretation of recurrent parasitaemia and drug treat-
ment regimens in P. vivax is complicated by the presence
of hypnozoites. Although the transmission of P. vivax in
the Iquitos area of Peru is relatively low, the possibility of
re-infection for the subjects in this study cannot be elimi-
nated. Paired samples with different initial and recurrent
haplotypes are the result of relapse with a heterologous
hypnozoite or a new infection; here, 50% of the paired
samples had different parasite lineages. Paired samples
with the same lineage (here, 50%) are the result of recrudes-
cence of the blood stage parasite (potentially a chloroquine
treatment failure), relapse with a homologous hypnozoite
(potentially a primaquine treatment failure), or a new in-
fection with the same parasite strain. Furthermore, the
population-level analysis here indicates that 90.2% of the
paired samples that had the same haplotype were unlikely
due to a new infection. These results indicate a potential
large frequency of recurrent infections resulting from
hypnozoite activation, either heterologous or homologous.
This could arise from either an initial infection or multiple
infections over time with different P. vivax strains, all
resulting in dormant hypnozoites. The activation of heter-
ologous hypnozoites has been noted before in patients
from Asia [9].
There are limitations to microsatellite, tandem repeats,
and PCR-based techniques to discern treatment outcomes.
PCR bias, potential artifacts, and the inability to dis-
criminate multiple clones are significant hurdles with these
methods [14]. Indeed, microsatellite diversity is associated
with the underlying repeat motif structure of each loci, and,
thus, there may be an inherent bias in the results based on
the loci that are chosen [32,34,37]. Careful consideration of
the underlying motif structure of these loci is an important
factor for researchers to consider. Further, the ability to
rapidly screen many infections and assess genetic variation
of the larger parasite population is key to understanding
and interpreting these assays, irrespective of the locus.Population-based approaches have an advantage over
smaller sampling strategies in both analyses and assess-
ments [15].
In conclusion, the P. vivax parasite population in the
Peruvian Amazon has considerable diversity and population
differentiation. Antigen and microsatellite-based P. vivax
genotyping methods can be useful tools to evaluate drug
treatment regimens and characterize genetic profiles of
parasite populations; however, researchers should be
careful when interpreting data. Antigen-encoding loci do
incorporate a bias due to immune selection. The descrip-
tion of the extent of hypnozoite activation in this popula-
tion emphasizes the importance of treatments that target
this stage. The P. vivax dormant hypnozoite stage poses
challenges in the assessment of paired patient samples;
nevertheless, population-based studies with appropriate
methods can provide insights into the biology and epidemi-
ology of P. vivax populations. The further development and
assessment of molecular tools that allow a broad analysis
of an individual parasite’s genetic construction will be im-
mensely useful to drug treatment and resistance studies.Competing interests
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